Aspirin Dosing in Pregnancy

Recruiting now · Early Phase 1

Conditions studied: Preeclampsia Possible

In brief

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

Key facts

Study ID

NCT07525635

Run by

NYU Langone Health

People needed

30

Starts

2026-04-27

Expected to finish

2028-02-20

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Pregnant people prior to 17 weeks
• Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
• Age 18-50 years
• Singleton viable gestation
• Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

You may not qualify if…

• Undergoing glucose challenge test (GCT) at time of blood draw
• Allergy or intolerance to aspirin
• Antithrombotic or antiplatelet therapy
• Anemia (hemoglobin <10 g/dl) or thrombocytopenia (platelet count <100,000), or thrombocytosis (platelet count >600,000)
• Known hemorrhagic diathesis
• Planned delivery outside of NYU

Where it is running

• NYU Langone Health — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.